WARFARIN SODIUM tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

WARFARIN SODIUM (UNII: 6153CWM0CL) (WARFARIN - UNII:5Q7ZVV76EI)

Available from:

Zydus Pharmaceuticals USA Inc.

INN (International Name):

WARFARIN SODIUM

Composition:

WARFARIN SODIUM 1 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Warfarin sodium tablets,USP are indicated for: - Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). - Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. - Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets, USP have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. Warfarin sodium tablets are contraindicated in: - Pregnancy Warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high

Product summary:

Warfarin Sodium Tablets USP, 1 mg are pink, oval, flat, beveled edge, uncoated tablets debossed with the logo of  'WAR', '1' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-052-01 in bottles of 100 tablets NDC 68382-052-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 2 mg are lavender, oval, flat, beveled edge, uncoated tablets debossed with the logo of  'WAR', '2' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-053-01 in bottles of 100 tablets NDC 68382-053-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 2.5 mg are green, oval, flat, beveled edge, uncoated tablets debossed with the logo of  'WAR', '2½' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-064-01 in bottles of 100 tablets NDC 68382-064-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 3 mg are tan, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '3' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-054-01 in bottles of 100 tablets NDC 68382-054-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 4 mg are blue, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '4' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-055-01 in bottles of 100 tablets NDC 68382-055-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 5 mg are peach, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '5' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-056-16 in bottles of 90 tablets NDC 68382-056-01 in bottles of 100 tablets NDC 68382-056-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 6 mg are teal, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '6' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-057-01 in bottles of 100 tablets NDC 68382-057-10 in bottles of 1000 tablets Warfarin Sodium Tablets USP, 7.5 mg are yellow, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '7½' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-058-01 in bottles of 100 tablets Warfarin Sodium Tablets USP, 10 mg are white to off white, oval, flat, beveled edge, uncoated tablets debossed with the logo of 'WAR', '10' and bisect on one side and plain on other side and are supplied as follows: NDC 68382-059-01 in bottles of 100 tablets Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP. Special Handling Procedures for proper handling and disposal of potentially hazardous drugs should be considered. Guidelines on this subject have been published [see References (15)] . Pharmacy and clinical personnel who are pregnant should avoid exposure to crushed or broken tablets [see Use in Special Populations (8.1)] .

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

Zydus Pharmaceuticals USA Inc.
----------
MEDICATION GUIDE
Warfarin (WAR far in) Sodium Tablets, USP
Read this Medication Guide before you start taking warfarin sodium and
each time you get a refill. There
may be new information. This Medication Guide does not take the place
of talking to your healthcare
provider about your medical condition or treatment. You and your
healthcare provider should talk about
warfarin sodium when you start taking it and at regular checkups.
What is the most important information I should know about warfarin
sodium?
Warfarin sodium can cause bleeding which can be serious and sometimes
lead to death. This is because
warfarin sodium is a blood thinner medicine that lowers the chance of
blood clots forming in your body.
•
You may have a higher risk of bleeding if you take warfarin sodium
and:
• are 65 years of age or older
• have a history of stomach or intestinal bleeding
• have high blood pressure (hypertension)
• have a history of stroke, or "mini-stroke" (transient ischemic
attack or TIA)
• have serious heart disease
• have a low blood count or cancer
• have had trauma, such as an accident or surgery
• have kidney problems
• take other medicines that increase your risk of bleeding,
including:
• a medicine that contains heparin
• other medicines to prevent or treat blood clots
• nonsteroidal anti-inflammatory drugs (NSAIDs)
• take warfarin sodium for a long time. Warfarin sodium, USP is the
active ingredient in warfarin
sodium.
Tell your healthcare provider if you take any of these medicines. Ask
your healthcare provider if you are not
sure if your medicine is one listed above.
Many other medicines can interact with warfarin sodium and affect the
dose you need or increase warfarin
sodium side effects. Do not change or stop any of your medicines or
start any new medicines before you talk
to your healthcare provider.
Do not take other medicines that contain warfarin sodium while taking
warfarin sodium.
•
Get your regular blood test to check for your respons

Summary of Product characteristics

WARFARIN SODIUM - WARFARIN SODIUM TABLET
ZYDUS PHARMACEUTICALS USA INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
WARFARIN SODIUM SAFELY
AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR WARFARIN SODIUM.
WARFARIN SODIUM TABLETS, USP
INITIAL U.S. APPROVAL: 1954
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WARNING: BLEEDING RISK
WARFARIN SODIUM CAN CAUSE MAJOR OR FATAL BLEEDING.(5.1)
PERFORM REGULAR MONITORING OF INR IN ALL TREATED PATIENTS. (2.1)
DRUGS, DIETARY CHANGES, AND OTHER FACTORS AFFECT INR LEVELS ACHIEVED
WITH WARFARIN
SODIUM THERAPY. (7)
INSTRUCT PATIENTS ABOUT PREVENTION MEASURES TO MINIMIZE RISK OF
BLEEDING AND TO
REPORT SIGNS AND SYMPTOMS OF BLEEDING. (17)
INDICATIONS AND USAGE
Warfarin sodium tablets, USP are a vitamin K antagonist indicated for:
Prophylaxis and treatment of venous thrombosis and its extension,
pulmonary embolism (1)
Prophylaxis and treatment of thromboembolic complications associated
with atrial fibrillation and/or
cardiac valve replacement (1)
Reduction in the risk of death, recurrent myocardial infarction, and
thromboembolic events such as
stroke or systemic embolization after myocardial infarction (1)
LIMITATIONS OF USE
Warfarin sodium tablets, USP have no direct effect on an established
thrombus, nor does it reverse
ischemic tissue damage. (1)
DOSAGE AND ADMINISTRATION
Individualize dosing regimen for each patient, and adjust based on INR
response. (2.1, 2.2)
Knowledge of genotype can inform initial dose selection. (2.3)
Monitoring: Obtain daily INR determinations upon initiation until
stable in the therapeutic range. Obtain
subsequent INR determinations every 1 to 4 weeks. (2.4)
Review conversion instructions from other anticoagulants. (2.8)
DOSAGE FORMS AND STRENGTHS
Scored tablets: 1, 2, 2.5, 3, 4, 5, 6, 7.5, or 10 mg (3)
CONTRAINDICATIONS
Pregnancy, except in women with mechanical heart valves (4, 5.5, 8.1)
Hemorrhagic tendencies or blood dyscrasias (4))
Recent or contemplated surg